Lung transplantation: opportunities for research and clinical advancement.
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. However, the success of lung transplantation is limited by many factors: (1) Too few lungs available for transplantation due to limited donors or injury to the donor lung; (2) current methods of preservation of excised lungs do not allow extended periods of time between procurement and implantation; (3) acute graft failure is more common with lungs than other solid organs, thus contributing to poorer short-term survival after lung transplant compared with that for recipients of other organs; (4) lung transplant recipients are particularly vulnerable to pulmonary infections; and (5) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term survival. Scientific advances may provide significant improvements in the outcome of lung transplantation. The National Heart, Lung, and Blood Institute convened a working group of investigators on June 14-15, 2004, in Bethesda, Maryland, to identify opportunities for scientific advancement in lung transplantation, including basic and clinical research. This workshop provides a framework to identify critical issues related to clinical lung transplantation, and to delineate important areas for productive scientific investigation.
Wilkes
David S
DS
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Egan
Thomas M
TM
Reynolds
Herbert Y
HY
D000208:Acute Disease; D000917:Antibody Formation / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology; D001989:Bronchiolitis Obliterans / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018925:Chemokines / Q000276:immunology; D002908:Chronic Disease; D003428:Cross Infection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006085:Graft Survival; D006287:Health Planning Guidelines; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods* / Q000592:standards; D016040:Lung Transplantation / Q000009:adverse effects / Q000276:immunology / Q000706:statistics & numerical data; D020380:Needs Assessment; D018579:Patient Selection; D019990:Perioperative Care / Q000458:organization & administration*; D012106:Research / Q000458:organization & administration*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D009927:Tissue and Organ Procurement / Q000458:organization & administration*; D023001:Transplantation Tolerance; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014850:Waiting Lists
D018925:Chemokines